View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 9, 2020

Arrakis Therapeutics signs drug discovery deal with Roche

Arrakis Therapeutics has signed a collaboration and licence agreement with Roche to identify RNA-targeted small molecule (rSM) drugs against various in different therapeutic areas.

Arrakis Therapeutics has signed a collaboration and licence agreement with Roche to identify RNA-targeted small molecule (rSM) drugs against various targets in different therapeutic areas.

The programme will leverage Arrakis’ RNA-targeted small molecule drug discovery platform, which combines RNA bioinformatic and structural tools, chemical libraries, RNA-specific assays and RNA-guided medicinal chemistry.

Under the deal, Arrakis will conduct discovery and research activities for each target to a specific phase and Roche will then hold the right to solely be responsible for further preclinical and clinical development.

Arrakis plans to explore a variety of mechanisms across the RNA lifecycle.

Arrakis Therapeutics founder and chief scientific officer Jennifer Petter said: “Through our pioneering work in RNA biology, we have built a platform for creating and adapting drug discovery tools that allow us to predict and validate the structure of RNA targets, locate druggable pockets, identify drug-like hits, and conduct medicinal chemistry programs to discover a new class of RNA-targeted medicines optimized for potency, selectivity and safety.”

Roche will make an upfront payment of $190m in cash to Arrakis, also eligible for preclinical, clinical, commercial and sales milestones, as well as royalties.

The total future payments to Arrakis are said to be worth several billions, contingent on regulatory approvals and other conditions.

Arrakis Therapeutics CEO Michael Gilman said: “The collaboration will increase the number of new treatments for patients arising from our proprietary rSM discovery platform.

“In addition to the Roche collaboration, we are further building our capabilities and advancing our wholly-owned rSM programmes for diseases unaddressed by today’s medicines.”

Apart from partnerships, Arrakis is internally working on rSMs for various difficult-to-treat diseases, such as cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU